CME SYMPOSIA

Primetime CME Symposium

The Intersection of NASH and Cardiometabolic Diseases: Implications for Screening, Diagnosis, and Management

This activity is jointly provided by Partners for Advancing Clinical Education and Cardiometabolic Health Congress.

Supported by an educational grant from Novo Nordisk. 

CHAIRED BY:
Robert H. Eckel, MD

Thursday, October 20
1:50 PM - 2:50 PM

Learning Objectives:

After completing this activity, the participant should be better able to:

  • Review the rationale, efficacy and safety of GLP-1 RAs for the treatment of NASH.
  • Summarize the current guidelines and recommendations for treatment of NASH, including recent consensus statements.
  • Review emerging NASH pharmacotherapies that aim to target various metabolic, inflammatory, and fibrotic pathways involved in disease progression.
Picture1
Cmhc Logo Color Lg

This activity is approved for AMA PRA Category 1 CreditsTM and is eligible for ABIM MOC, ACPE, ANCC and CDR credit, see final activity announcement for specific details. Full CME information to come.

Sunrise CME Breakfast Symposium

Navigating the Diagnosis and Treatment of Patients with Narcolepsy and Cardiovascular Risk

This activity is jointly provided by Partners for Advancing Clinical Education and Cardiometabolic Health Congress. Held in partnership with the American Academy of Cardiovascular Sleep Medicine.

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

CHAIRED BY:
Virend K. Somers, MD, PhD

Friday, October 21
7:00 AM - 8:00 AM

Learning Objectives:

After completing this activity, the participant should be better able to:

  • Recognize that cardiometabolic risk factors are common in patients with narcolepsy.
  • Describe the pathophysiological connections between narcolepsy and increased cardiometabolic risk.
  • Explain the rationale and evidence behind the increased risk for major adverse cardiovascular events with commonly used narcolepsy agents.
  • Summarize recent updates with new and emerging narcolepsy treatments.
  • Select individualized treatment plans for narcolepsy patients with or at-risk for cardiovascular.
Picture1
Cmhc Logo Color Lg

 This activity is approved for AMA PRA Category 1 CreditsTM and is eligible for ABIM MOC, ACPE, ANCC and CDR credit, see final activity announcement for specific details. Full CME information to come.

CME Session

Why Should We Use CGM in Patients with Type 2 Diabetes? Assessing the Evidence and Practical Pearls for Integration

This activity is jointly provided by Partners for Advancing Clinical Education and Cardiometabolic Health Congress.

Supported by an educational grant from Dexcom.

Irl B. Hirsch, MD

PRESENTED BY:
Irl B. Hirsch MD

Friday, October 21
1:45 PM – 2:10 PM

Learning Objectives:

After completing this activity, the participant should be better able to:

  • Discuss the mechanisms of action and different properties of GLP-1 RAs.
  • Summarize the efficacy and safety of GLP-1 RAs, alone or in combination, for the management of T2DM.
  • Review the current evidence from CVOTs and real-world studies with GLP-1 RAs and their practice implications in managing T2DM patients with CVD or at CVD risk.
  • List recent guideline updates about the individualization of T2DM therapy in patients with existing CVD or CVD risk.
  • Select individualized treatment strategies for patients with T2DM that optimize glycemic control and reduce overall CVD risk.
Cmhc Logo Color Lg

This activity is approved for AMA PRA Category 1 CreditsTM and is eligible for ABIM MOC, ACPE, ANCC and CDR credit, see final activity announcement for specific details. Full CME information to come.

Primetime CME Symposium

Assessing the Evolving Role of GLP1-RAs to Reduce Cardiovascular Risk: Emerging Evidence, Evolving Guidance, and Expert Perspectives

This activity is jointly provided by Partners for Advancing Clinical Education and Cardiometabolic Health Congress.

Supported by an educational grant from Novo Nordisk.

Vanita R. Aroda, MD

CHAIRED BY:
Vanita R. Aroda, MD

Friday, October 21
2:10 PM – 3:10 PM

Learning Objectives:

After completing this activity, the participant should be better able to:

  • Discuss the mechanisms of action and different properties of GLP-1 RAs.
  • Summarize the efficacy and safety of GLP-1 RAs, alone or in combination, for the management of T2DM.
  • Review the current evidence from CVOTs and real-world studies with GLP-1 RAs and their practice implications in managing T2DM patients with CVD or at CVD risk.
  • List recent guideline updates about the individualization of T2DM therapy in patients with existing CVD or CVD risk.
  • Select individualized treatment strategies for patients with T2DM that optimize glycemic control and reduce overall CVD risk.
Cmhc Logo Color Lg

This activity is approved for AMA PRA Category 1 CreditsTM and is eligible for ABIM MOC, ACPE, ANCC and CDR credit, see final activity announcement for specific details. Full CME information to come.

Primetime CME Symposium

The Disproportionate Burden of Atrial Fibrillation in High-Risk African American Patients with Cardiometabolic Comorbidities

This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

Supported by an educational grant from Janssen Scientific Affairs, LLC.

CHAIRED BY:
Keith C. Ferdinand, MD

Saturday, October 22
9:50 AM – 10:50 AM

Learning Objectives:

After completing this activity, the participant should be better able to:

  • Recognize the prevalence, burden, and potential increased risk of undiagnosed AF in high-risk African American patients.
  • Select screening criteria and emerging technological approaches in order to timely diagnose AF in African Americans.
  • Summarize recent evidence with DOACs in cardiometabolic patients with AF, as well as race-specific efficacy and safety data.
  • Identify individualized treatment regimens for stroke prevention in high-risk African American patients with atrial fibrillation and cardiometabolic comorbidities based on current guidelines, RCT and real-world evidence, as well as patient-specific factors.
EDUCATION GROUP Global UMA Copy
Cmhc Logo Color Lg

This activity is approved for AMA PRA Category 1 CreditsTM and is eligible for ABIM MOC, ACPE, ANCC and CDR credit, see final activity announcement for specific details. Full CME information to come.

October 19-22, 2022

17th Annual Cardiometabolic Health Congress

Boston Park Plaza
50 Park Plaza At Arlington St
Boston, MA 02116

00
Days
00
Hours
00
Minutes
00
Seconds